Novo Nordisk filed for FDA approval of CagriSema in early 2026, with a review decision expected later this year
Poor sleep undermines peptide therapy effectiveness
Song W, Song G, Zhao C, Li X, Pei X, Zhao W, et al
Serious reactions are rare, but an allergic reaction is possible with any injection, which is another reason a first dose in trained hands is sensible
Regardless of their differences, all of these disorders are associated with intellectual disability, motor abnormalities, and behavioral abnormalities
Potential risks include: Infection risk if injections are administered in non-clinical settings without appropriate sterile technique Allergic reactions to any component of the formulation Liver toxicity theoretical concern with excessive methionine or choline Drug interactions particularly if combined with other supplements or medications Unknown long-term effects due to absence of longitudinal safety data The MHRA advises caution with unlicensed injectable products, as quality, purity, and sterility cannot be guaranteed
